Rosenberger Brian 4
4 · Zynerba Pharmaceuticals, Inc. · Filed Sep 14, 2023
Insider Transaction Report
Form 4
Rosenberger Brian
VP, Commercial
Transactions
- Award
Common Stock
2023-09-12+22,200→ 255,970 total - Sale
Common Stock
2023-09-13$1.33/sh−6,411$8,499→ 249,559 total
Footnotes (2)
- [F1]On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 22,200 performance-based restricted stock awards granted in a prior year.
- [F2]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.